# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 2561-2570 of 2727 results.
Genetically-informed Therapies for Patients With Metastatic Cancer
Status: Withdrawn
Last Changed: Jul 14, 2014
First Received: Dec 04, 2013
Disease(s): Metastatic Cancer
Intervention(s): Genetically Informed Therapy
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Status: Recruiting
Last Changed: Oct 14, 2020
First Received: Mar 24, 2020
Disease(s): Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer
Intervention(s): ACE1702, Cyclophosphamide, Fludarabine
Locations: Northwestern Univeristy, Chicago, Illinois, United States
MD Anderson Cancer Center, Houston, Texas, United States
Peninsula Cancer Institute, Newport News, Virginia, United States
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
Status: Completed
Last Changed: Sep 27, 2011
First Received: Jan 29, 2008
Disease(s): Advanced Solid Tumors
Intervention(s): OSI-930 and erlotinib
Locations: H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1
Status: Completed
Last Changed: Mar 10, 2015
First Received: Nov 04, 2010
Disease(s): Solid Tumor
Intervention(s): IMF-001
Locations: Roswell Park Cancer Institute, Buffalo, New York, United States
New York University (NYU) Cancer Center, New York, New York, United States
A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes
Status: Recruiting
Last Changed: Sep 10, 2020
First Received: Nov 21, 2019
Disease(s): Solid Tumor
Intervention(s): Rucaparib
Locations: Innovative Clinical Research Institute, Glendale, California, United States
UCLA Medicine Hematology and Oncology, Los Angeles, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Florida Cancer Specialists, Fort Myers, Florida, United States
Florida Cancer Specialists, Saint Petersburg, Florida, United States
... and 17 other locations.
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
Status: Completed
Last Changed: Sep 27, 2012
First Received: Nov 04, 2005
Disease(s): Tumors
Intervention(s): NB1011
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of Minnesota, Minneapolis, Minnesota, United States
Princess Margaret Hospital, Toronto, Ontario, Canada
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active, not recruiting
Last Changed: Oct 19, 2020
First Received: Oct 23, 2014
Disease(s): Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Intervention(s): Adavosertib, Paclitaxel, Carboplatin, Gemcitabine, PLD
Locations: Research Site, Gilbert, Arizona, United States
Research Site, Tucson, Arizona, United States
Research Site, La Jolla, California, United States
Research Site, Los Angeles, California, United States
Research Site, San Francisco, California, United States
... and 14 other locations.
Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant
Status: Completed
Last Changed: Nov 05, 2010
First Received: Aug 07, 2006
Disease(s): Cancer
Intervention(s): graft versus host disease prophylaxis/therapy, fluorescence in situ hybridization, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, in vitro-treated bone marrow transplantation, management of therapy complications
Locations: Geauga Regional Hospital, Cleveland, Ohio, United States
Lake/University Ireland Cancer Center, Cleveland, Ohio, United States
Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
University Suburban Health Center, Cleveland, Ohio, United States
UHHS Chagrin Highlands Medical Center, Cleveland, Ohio, United States
... and 4 other locations.
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Status: Recruiting
Last Changed: Oct 27, 2020
First Received: Jan 29, 2019
Disease(s): HER2-expressing Cancers
Intervention(s): ZW49
Locations: City of Hope, Duarte, California, United States
Stanford University School of Medicine, Palo Alto, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
University of Chicago Medicine, Chicago, Illinois, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
... and 8 other locations.
Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC
Status: Recruiting
Last Changed: Oct 29, 2020
First Received: Jun 18, 2019
Disease(s): Solid Tumor
Intervention(s): RMC-4630, Cobimetinib, Drug: Osimertinib
Locations: Honor Health Research Institute, Scottsdale, Arizona, United States
City of Hope, Duarte, California, United States
UC Irvine - Chao Family Comprehensive Cancer Center, Orange, California, United States
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
UC San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
... and 17 other locations.